Vertex Pharma stock holds up as guidance and pipeline support a $548 level

Vertex Pharma (US92532F1003) stock is trading at $548.05 per share as of August 21, 2026, reflecting a market capitalization of $138.92 billion and a premium valuation for its cystic fibrosis franchise and expanding pipeline per a recent market-data overview. A detailed quote snapshot shows shares changing hands at $548.05, with a price-to-earnings ratio of 31.43 based on current-year earnings expectations.

Per the same August 21, 2026 trading summary, Vertex Pharma shares traded between an intraday low of $540.05 and a high of $555.31, leaving the current price 1.5 percent above the low and 1.3 percent below the high in that session. The quote data highlight that investors are keeping the stock close to its recent peak, suggesting confidence in current guidance and late-stage programs.

Latest quarter shows double-digit revenue growth

Vertex Pharma recently reported quarterly revenue of $3.33 billion for its most recent interim period, with that figure rising 12.5 percent year over year and exceeding consensus estimates of $3.23 billion per an earnings recap published on August 22, 2026. The same recap notes that adjusted earnings per share came in at $4.73 for the quarter, narrowly missing the $4.74 consensus by $0.01 while still marking growth from $4.52 in the prior-year period.

Profitability metrics remain strong, with the latest quarterly report showing a net margin of 35.00 percent and a return on equity of 23.09 percent for Vertex Pharma. This combination of double-digit revenue growth and high margins underpins the company’s cash-generation profile despite the slight earnings-per-share shortfall versus analyst expectations.

Guidance and analyst view support valuation

Current-year expectations remain constructive, with research coverage indicating that analysts, as a group, forecast 2026 full-year earnings per share of 16.86 for Vertex Pharma. The same coverage characterizes the stock’s consensus rating as Moderate Buy and cites an average price target of $563.50, modestly above the present trading level.

Additional commentary from institutional-investor filings and research digests points to Vertex Pharma’s leadership in cystic fibrosis therapies and notes that recent corporate updates have included raising full-year 2026 revenue guidance, reflecting confidence in ongoing demand and new product contributions. A market overview highlights that the guidance upgrade and pipeline momentum have become key elements in the bull case for the stock in August 2026.

Pipeline progress in kidney disease adds to growth story

Beyond cystic fibrosis, Vertex Pharma is working to diversify its revenue base through programs in areas such as APOL1-mediated kidney disease. Recent coverage in August 2026 notes that the company has completed a Phase 2b clinical trial for inaxaplin, its candidate targeting this genetic kidney condition, marking a meaningful milestone that could support future regulatory interactions and commercialization plans if later-stage data confirm benefit. The digest describes the completed Phase 2b study as an important non-cystic-fibrosis growth driver that could complement the company’s established franchise.

Analyst commentary collected in late August 2026 underscores that the cystic fibrosis portfolio continues to act as an earnings engine for Vertex Pharma, while newer therapies and investigational assets, including inaxaplin, are expected to broaden the company’s revenue mix over the medium term. The same roundup emphasizes that investors are watching pipeline inflection points closely as potential catalysts for the stock.

Cystic fibrosis therapies remain core cash engine

Vertex Pharma built its business around research-driven drug development, and its cystic fibrosis franchise remains the primary contributor to revenue and earnings in 2026. The company’s portfolio of CFTR modulators, which target the underlying protein dysfunction in cystic fibrosis, has transformed standards of care for eligible patients by improving lung function and overall health outcomes. Background commentary on Vertex describes cystic fibrosis as a continuing engine for the firm’s rally and cash generation.

The durable nature of this franchise gives Vertex Pharma financial flexibility to invest in new indications, including sickle cell disease and other genetic disorders, while maintaining strong profitability metrics. Combined with the company’s raised 2026 revenue guidance and double-digit quarterly revenue growth reported in the latest period, the cystic fibrosis portfolio continues to underpin investor confidence in the stock around the mid-$500 range as of late August 2026.

Vertex Pharma product focus

Within its cystic fibrosis portfolio, Vertex Pharma markets combination therapies that enhance CFTR function and address multiple mutation types, offering disease-modifying treatment options for many patients living with cystic fibrosis. These products generate a large share of the company’s $3.33 billion in quarterly revenue reported for the latest period, and their performance plays a central role in supporting the raised full-year 2026 revenue guidance referenced in recent market data and research summaries. As investors assess Vertex Pharma’s pipeline opportunities in kidney disease and other indications, the established cystic fibrosis therapies remain the backbone of the business model and a key reason the stock commands a valuation consistent with a 31.43 price-to-earnings ratio.

Vertex Pharma stock and trading context

Vertex Pharma shares trade on the Nasdaq under the ticker VRTX. As of the completed trading session on August 21, 2026, a quote snapshot shows the stock at $548.05, with a daily range between $540.05 and $555.31 and a market capitalization of $138.92 billion. The same data indicate that at the $548.05 level, Vertex Pharma stock sits slightly below its recent intraday high but remains well-supported by strong fundamental trends and an analyst consensus price target of $563.50.

Read more

More on Vertex Pharma stock at the company’s investor relations site.

Fact box

Company: Vertex Pharma Inc.

ISIN: US92532F1003

Ticker: VRTX

Exchange: Nasdaq

Price (as of August 21, 2026, 4:00 p.m. ET): $548.05 USD

Market cap: $138.92 billion (as of August 21, 2026)

Sector / Industry: Health care / Biotechnology

Index membership: S&P 500